Mon panier

Flt-3 Ligand

Flt-3 Ligand Informations sur la molécule

Nom anglaisFms-related tyrosine kinase 3 ligandNombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cibleFlt3L,SL cytokine,FLT3LG
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisFms-related tyrosine kinase 3 ligand
Alias de la cibleFlt3L,SL cytokine,FLT3LG
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

Flt-3 Ligand Liste de produits

  • Attribut

    Protein (11)Kits (1)

  • Bibliothèque de produits

    En ligne (12)

  • Espèces

    Human (9)Mouse (1)Rhinopithecus bieti (1)Canine (1)

  • Étiquette

    His Tag (5)Tag Free (5)His Tag & Avi Tag (1)- (1)

  • Marqueur

    Unconjugated (10)Biotin-labeled (1)- (1)

Flt-3 LigandContexte de la molécule

FMS-like tyrosine kinase 3 ligand (Flt-3 Ligand) is also known as FL, Flt3L and FLT3LG, is an α-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages. FLT3LG is expressed as a noncovalentlylinked dimer by T cells and bone marrow and thymic fibroblasts. Each 36 kDa chain carries approximately 12 kDa of N- and O- linked carbohydrates. FLT3LG is structurally homologous to stem cell factor (SCF) and colony stimulating facor 1 (CSF-1). FLT3LG acts as a growth factor that increases the number of immune cells by activating the hematopoietic progenitors. It also induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3LG induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation. FLT3LG cooperates with IL2, IL6, IL7, and IL15 to induce NK cell development and with IL3, IL7 and IL11 to induce terminal B cell maturation. Animal studies also show FLT3LG to reduce the severity of experimentally induced allergic inflammation. FLT3LG is crucial for steady-state pDC and cDC development. A lack of FLT3L results in low levels of DCs.

Flt-3 LigandAlias de la molécule

FLT3LG,FL,FLT3L,Flt3 ligand

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
AdezkibartAMG 329; HZN-1116; VIB-1116Phase 2 ClinicalViela Bio IncAutoimmune Diseases; Rheumatic Diseases; Sjogren's Syndrome
Details
MQ-710MQ-710Phase 1 ClinicalImvaq Therapeutics Corp, Memorial Sloan Kettering Cancer CenterAdenocarcinoma, Sebaceous; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Hemangiosarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Paget Disease, Extramammary; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques